Wockhardt Ltd — earnings calls

Wockhardt reported FY26 revenue of INR3,373 crores with EBITDA of about INR630 crores, EBITDA growth of 51%, and profit before tax of INR238 crores, while EBITDA margin rose from 5.4% three years ago to 18.6%. Management described Zaynich, its novel antibiotic, receiving US FDA approval as a major milestone and laid out launch plans for the US, India, and emerging markets, alongside growth of 35% in the biosimilar business and 27% growth in the specialty segment. Executives also discussed capex plans, patent life, manufacturing strategy across India and Europe, and commercial partnership structures for the US launch.